Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Inozyme Pharma, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −8 vs. Q2 2022
- Shares held
- 30.8M
- −711.2K (−2.3%) vs. Q2 2022
- Total value
- $82.7M
- −$66.7M (−44.7%) vs. Q2 2022
- New holders
- 2
- 11 more added
- Sold out
- 10
- 15 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INZY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 87 | $202.3M |
| Q1 2025 | 97 | $42.5M |
| Q4 2024 | 105 | $145.1M |
| Q3 2024 | 89 | $285.5M |
| Q2 2024 | 90 | $240.1M |
| Q1 2024 | 89 | $382.0M |
| Q4 2023 | 80 | $213.3M |
| Q3 2023 | 77 | $204.6M |
| Q2 2023 | 74 | $190.3M |
| Q1 2023 | 50 | $183.4M |
| Q4 2022 | 37 | $30.4M |
| Q3 2022 | 39 | $82.7M |
| Q2 2022 | 47 | $149.4M |
| Q1 2022 | 50 | $71.2M |
| Q4 2021 | 51 | $118.2M |
| Q3 2021 | 52 | $202.7M |
| Q2 2021 | 50 | $337.1M |
| Q1 2021 | 55 | $379.4M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Inozyme Pharma, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 157 | $0 | 0.00% | −20−11.3% | Reduced |
| Crewe Advisors LLC | 163 | $0 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 60 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 690 | $2.00K | 0.00% | +221+47.1% | Added |
| Federated Hermes, Inc. | 1,533 | $4.00K | 0.00% | +1,533 | New |
| Bank of America Corp | 2,927 | $8.00K | 0.00% | +2,920+41,714.3% | Added |
| Barclays PLC | 6,403 | $17.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 13,183 | $35.0K | 0.00% | +13,183 | New |
| Charles Schwab Investment Management Inc | 16,549 | $45.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 20,243 | $54.0K | 0.00% | −1,655−7.6% | Reduced |
| Morgan Stanley | 22,284 | $59.0K | 0.00% | −18,890−45.9% | Reduced |
| Dimensional Fund Advisors LP | 27,043 | $73.0K | 0.00% | +13,956+106.6% | Added |
| Northern Trust Corp | 40,304 | $108.0K | 0.00% | −6,686−14.2% | Reduced |
| State of Wisconsin Investment Board | 48,800 | $131.0K | 0.00% | −20,100−29.2% | Reduced |
| Overbrook Management Corp | 69,326 | $186.0K | 0.05% | 00.0% | Unchanged |
| State Street Corp | 76,355 | $205.0K | 0.00% | +27,300+55.7% | Added |
| Citadel Advisors LLC | 110,648 | $297.0K | 0.00% | −10,179−8.4% | Reduced |
| Walleye Capital LLC | 117,529 | $315.0K | 0.01% | +16,087+15.9% | Added |
| Bridgeway Capital Management, LLC | 133,400 | $358.0K | 0.01% | +46,000+52.6% | Added |
| Renaissance Technologies LLC | 155,400 | $416.0K | 0.00% | +37,100+31.4% | Added |
| UBS Oconnor LLC | 165,498 | $444.0K | 0.01% | −5,849−3.4% | Reduced |
| Millennium Management LLC | 170,184 | $456.0K | 0.00% | −2,908−1.7% | Reduced |
| Geode Capital Management, LLC | 233,685 | $626.0K | 0.00% | +16,760+7.7% | Added |
| Laurion Capital Management LP | 271,800 | $728.0K | 0.02% | 00.0% | Unchanged |
| BlackRock Inc. | 428,431 | $1.15M | 0.00% | −2,089−0.5% | Reduced |
| FMR LLC | 609,380 | $1.63M | 0.00% | −439−0.1% | Reduced |
| MPM Oncology Impact Management LP | 661,144 | $1.77M | 0.42% | −3,836−0.6% | Reduced |
| Janus Henderson Group PLC | 705,577 | $1.91M | 0.00% | −224,379−24.1% | Reduced |
| Sphera Funds Management Ltd. | 1,175,058 | $3.15M | 0.56% | +9,458+0.8% | Added |
| Vanguard Group Inc | 1,343,063 | $3.60M | 0.00% | −11,153−0.8% | Reduced |
| CHI Advisors LLC | 1,996,277 | $5.35M | 1.44% | −37,525−1.8% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 2,090,436 | $5.60M | 0.11% | −605,936−22.5% | Reduced |
| NEA Management Company, LLC | 2,444,379 | $6.55M | 0.33% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,596,672 | $6.96M | 0.02% | +50,000+2.0% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,661,154 | $7.13M | 2.61% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,709,987 | $7.26M | 1.12% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 2,807,618 | $7.52M | 0.19% | +167,562+6.3% | Added |
| Deep Track Capital, LP | 3,250,000 | $8.71M | 0.43% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 3,655,308 | $9.80M | 0.62% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −106,999−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −25,649−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −12,505−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,179−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −4,800−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −117−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −143−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −115−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −76−100.0% | Sold out |